XBiotech Inc. XBIT
Set alert
1.88 USD -0.06 -3.09%
At close · Oct 30
1.88 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
1.87 Day range 1.98
1.85 52-week range 2.94
- YTD
- -21.34%
- 1 year
- -21.67%
- Open
- 1.94
- Prev close
- 1.94
- Mkt cap
- 57.32M
- Vol
- 50.56K
- Avg vol
- 55.49K
- EPS
- -1.48
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.87
- High
- 1.98
- Forward P/E
- 34.62
- Beta
- 0.00
- Short ratio
- 15.03
- Inst. own
- 16.19%
- Dividend
- 0.00
- Ex-div date
- Jul 14, 2021
- Earnings
- Nov 9, 2023
- 50-d avg
- 7.07
- 200-d avg
- 7.11
- 1y target
- 0.00
3M chart
Signals (20)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 19, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| RSI: Overbought | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
Key statistics
- Market cap
- 137.18M
- Enterprise value
- 21.37M
- Trailing P/E
- 0.00
- Forward P/E
- 34.62
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.71
- EPS (TTM)
- -1.08
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -22.16M
- Total cash
- 183.12M
- Total debt
- 10.00M
- Return on equity
- -15.75%
- Shares outstanding
- 30.48M
- Short % of float
- 4.50%
- 50-day average
- 7.07
- 200-day average
- 7.11
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Nov 9, 2023
Expected Nov 9, 2023. Consensus EPS estimate 0.00.
Financials — quick view
XBIT Revenue — quarterly 0
XBIT Net income — quarterly -6.73M
XBIT EPS — quarterly -0.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.16 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -0.43 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.33 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 10, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 7, 2020 | Piper Sandler | main | — | Overweight |
| Dec 11, 2019 | Piper Sandler | main | — | Overweight |
| Jun 14, 2019 | Piper Sandler | init | — | Overweight |
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- xbiotech.com
News
- XBiotech Appoints Jan-Paul Simard Co-CEO, Effective Oct. 23
- XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing Threshold Of 42, More Surviving Patients
- XBiotech Says IND Application For V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path For U.S. Patient Enrollment
- XBiotech Q1 EPS $(0.18) Up From $(0.36) YoY
- XBiotech Announces John Simard To Retire As CEO, To Continue As Chairman; Sushma Shivaswamy Appointed Interim CEO
- XBiotech Q3 EPS $(0.20) Down From $(0.16) YoY
- XBiotech Q2 EPS $(0.06) Up From $(0.43) YoY
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on XBIT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 4.10% | 1,250,001 | 5.63M | Sep 29, 2024 |
| Vanguard Group Inc | 3.48% | 1,061,979 | 4.78M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.48% | 452,264 | 2.04M | Sep 29, 2024 |
| Millennium Management Llc | 0.92% | 281,019 | 1.26M | Sep 29, 2024 |
| UBS Asset Management Americas Inc | 0.83% | 253,770 | 1.14M | Sep 29, 2024 |
| State Street Corporation | 0.74% | 224,595 | 1.01M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.04% | 623,356 | 2.81M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.48% | 450,934 | 2.03M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.96% | 292,547 | 1.32M | Sep 29, 2024 |
| iShares Russell 2000 Value ETF | 0.62% | 187,801 | 845.10K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.61% | 186,990 | 841.46K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 111,517 | 501.83K | Oct 30, 2024 |